Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

RADIENT RESTRUCTURED BY A PLANNED REVERSE MERGER

Checkout my next post on how Provista Diagnostics Inc. will reverse merge with Radient Pharmaceuticals Corp according to the Letter of intent...LOI of 2010..After the merger we will be dropping the Radient name ..It will be replaced with Provista you understand...

Keep on hitting these previous I-Hub Links..There is a surprisea t the end you understand..It is the "Wolf Code"..Here is the latest..

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117114473

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$




Talpina Holdings LLC is a Delaware Limited-Liability Company (llc) filed on December 10, 2010. The company's File Number is listed as 4910856.
http://www.bizapedia.com/de/TALPINA-HOLDINGS-LLC.html

Talpina Holdings owns 20 per cent of preferred shares of Provista Diagnostics. They were born on December 10, 201..What was going on with RPC at the time prior to Talpina Holding Company that is involved with the 2010 LOI reverse merger between PDX and RXPC...NOTICE how they Talpina Holdings LLC incorporated in Delaware after the December 3, 2010 meeting...

Here is where the 28 MILLION in debt went to..RXPC STOCK you understand....And the Provista Diagnostics Inc. Angel investors who gave 11 million dollars to Radient, a/k/a Lenders are the Winners...Along with the Seal Team Strong ......ahooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo

Talpina Holdings didn't pump monies into Provista Diagnostics until two years later after the sale of Provista Diagnostics by William Gartner in (February) March 2012.....Here is the beginning of the 2010 LOI for reverse merger of Provista DX and radient .....You understand..ahooooooooooooooooooooooooooooooooooooo

Follow the monies..They lead from Provista Diagnostics to Radient not from or to Uni Pharma...you understand....

http://www.bizapedia.com/de/TALPINA-HOLDINGS-LLC.html


Corporation Name:
PROVISTA DIAGNOSTICS, INC

The application right after Global Cancer Diagnostics got exclusive rights to DR-70.....


APPLICATION FOR AUTHORITY 11/1/2012


http://ecorp.azcc.gov/Details/Corp?corpId=F17887633


D/A Documents [Amend]Notice of Exempt Offering of Securities, item 06
Acc-no: 0001539252-12-000006 (33 Act) Size: 11 KB 2012-09-21 021-174213
121103785
D Documents Notice of Exempt Offering of Securities, item 06
Acc-no: 0001539252-12-000005 (33 Act) Size: 12 KB 2012-03-01 021-174213
12658218
http://www.sec.gov/Archives/edgar/data/838879/000095012310104061/a56551ddef14a.htm



NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON December 3, 2010
10:00 AM
A Letter To Our Stockholders
From Our Chairman & CEO
We recently refocused our business on the development, manufacture and marketing of advanced, pioneering medical diagnostic products, including ONKO-SURE™, a proprietary In-Vitro Diagnostic (“IVD”) Cancer Test. We believe that, with an improved balance sheet and the right financial resources, we can position the Company to become a fast-growing and profitable enterprise. During the third and fourth quarter of 2009, we repositioned various business segments that we believe will enable us to monetize the value of some of our assets through either new partnerships, separate potential IPO’s or possible sales. These special assets include: (i) our 98% ownership in China-based pharmaceuticals business, Jade Pharmaceuticals Inc. (JPI); (ii) our 100% ownership of a proprietary cancer vaccine therapy technology: Combined Immunogene Therapy (“CIT”); and (iii) 100% ownership of the Elleuxe brand of advanced skin care products with proprietary formulations that include human placenta extract ingredients sourced from our China operations of JPI.

The Board of Directors of Radient Pharmaceuticals Corporation (“RPC”) is seeking stockholder approval at this Annual Stockholders Meeting, for what we have described as our Financial Stabilization Plan (the “Plan”). We have recently closed approximately $11,057,000 in additional financings through the sale of convertible notes and warrants. The issuance of the shares underlying the notes and warrants related to this financing require stockholder approval (please see Proposals 8, 9, 10 and 11 for details). Next, the Plan is focused around building on a highly improved balance sheet; which means we are seeking to gain approval for the above-noted share issuances, as well as the ability to exchange up to approximately $3,648,000 in notes and warrants issued in 2008 and 2009 (please see Proposal 1 and 3 for details). Lastly, we are proposing to create a new 2010 stock option plan that will incentivize management and employees to drive our In-vitro Diagnostics (“IVD”) business to new heights in sales and profitability in 2010 and beyond, please see Proposal 13 for details.


We Believe Our Plan Provides Significant Value to Our Existing Stockholders Despite the Dilution: We believe that the Plan will provide RPC with enough robust financial resources to execute RPC’s IVD business plan successfully. Yet, the Plan calls for the exchange of up to $28,654,000 in various debt obligations for shares of our common stock and the creation of a new incentive stock option plan for management and employees of up to a total of 6,000,000 shares. If all of the Proposals in this Proxy Statement are approved and the proposed transactions are completed at the floor pricing of $0.28 per share, the number of outstanding shares of common stock will be 164,288,249. Although this would result in an effective dilution for existing stockholders of approximately 84%, the Company and our stockholders will receive approximately $6,208,000 in net proceeds from our new financing arrangements, potential proceeds of up to $6,657,000 from the exercise of new warrants – if and when exercised, and benefit from the elimination of approximately $3,684,000 in debt. Management also believes that the Plan will be sufficient to cure the deficiencies cited by the NYSE Amex to satisfy their Continuing Listing Standards and allow us to remain in compliance therewith and avoid delisting.


http://www.sec.gov/Archives/edgar/data/838879/000095012310104061/a56551ddef14a.htm